|
|
OSUCCC
 |
Charles L. Shapiro, M.D.
Professor
College of Medicine
Internal Medicine - Hematology/Oncology
B421 Starling Loving
320 W. 10th Avenue Columbus,OH. 43210
o |
(614) 293-7530 |
f |
(614) 293-4372 |
|
Programs
|
 |
|
|
Current Publications
|
|
Cancer Chemother Pharmacol in press: , 2009
|
|
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
|
|
Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL
|
|
|
in press: , 2009
|
|
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
|
|
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd
|
|
|
Clin Adv Hematol Oncol 7(5): 319-20, 2009
|
|
Bisphosphonates as adjuvant therapy.
|
|
Shapiro CL
|
|
|
Mol Endocrinol 23(2): 176-87, 2009
|
|
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
|
|
Ramaswamy B, Majumder S, Roy S, Ghoshal K, Kutay H, Datta J, Younes M, Shapiro CL, Motiwala T, Jacob ST
|
|
|
Cancer 115(4): 899-908, 2009
|
|
Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
|
|
Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro CL
|
|
|
J Natl Compr Canc Netw 7 Suppl 3: S1-S32; quiz S33-S35, 2009
|
|
NCCN Task Force Report: Bone Health in Cancer Care.
|
|
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH
|
|
|
Carcinogenesis 30(10): 1702-9, 2009
|
|
OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling.
|
|
Weng JR, Tsai CH, Omar HA, Sargeant AM, Wang D, Kulp SK, Shapiro CL, Chen CS
|
|
|
J Clin Oncol 27(31): 5270-7, 2009
|
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
|
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd
|
|
|
J Cancer Surviv 3(1): 4-11, 2009
|
|
The LIVESTRONG Survivorship Center of Excellence Network.
|
|
Shapiro CL, McCabe MS, Syrjala KL, Friedman D, Jacobs LA, Ganz PA, Diller L, Campell M, Orcena K, Marcus AC
|
|
|
Breast Cancer Res Treat 117(1): 83-9, 2008
|
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
|
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL
|
|
|
J Clin Oncol 25(25): 3991-4008, 2008
|
|
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
|
|
Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ
|
|
|
Psychooncology 17(11): 1108-20, 2008
|
|
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.
|
|
Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA
|
|
|
Drugs 68(18): 2591-600, 2008
|
|
Aromatase inhibitor-associated bone loss: clinical considerations.
|
|
Pant S, Shapiro CL
|
|
|
J Natl Compr Canc Netw 5(8): 676-701, 2008
|
|
Breast cancer risk reduction.
|
|
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Sellin RV, Shapiro CL, Singletary E, Ward JH
|
|
|
Cancer 113(3): 638-47, 2008
|
|
Delayed emotional recovery after taxane-based chemotherapy.
|
|
Thornton LM, Carson WE, Shapiro CL, Farrar WB, Andersen BL
|
|
|
Breast Cancer Res Treat 115(1): 205-12, 2008
|
|
Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?
|
|
Beyer SJ, Jimenez RE, Shapiro CL, Cho JY, Jhiang SM
|
|
|
Carcinogenesis 29(7): 1459-65, 2008
|
|
Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer.
|
|
Rodriguez BA, Cheng AS, Yan PS, Potter D, Gosto-Perez FJ, Shapiro CL, Huang TH
|
|
|
J Biol Chem 283(44): 29897-903, 2008
|
|
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
|
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S
|
|
|
Cancer Chemother Pharmacol 63(6): 1073-82, 2008
|
|
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
|
|
Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA
|
|
|
Ann Oncol 19(8): 1417-22, 2008
|
|
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
|
|
Mrozek E, Kolesar J, Young DC, Allen J, Villalona-Calero M, Shapiro CL
|
|
|
J Clin Oncol 26(10): 1691-7, 2008
|
|
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
|
|
Puhalla S, Mrozek E, Young DC, Ottman S, McVey A, Kendra K, Merriman NJ, Knopp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL
|
|
|
J Clin Oncol 26(10): 1642-9, 2008
|
|
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
|
|
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C
|
|
|
Mol Cancer Ther 7(4): 800-8, 2008
|
|
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
|
|
Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS
|
|
|
Cancer 112(5): 1178-87, 2008
|
|
Surviving recurrence: psychological and quality-of-life recovery.
|
|
Yang HC, Thornton LM, Shapiro CL, Andersen BL
|
|
|
J Clin Oncol 26(9): 1567-9, 2008
|
|
Treatment of breast cancer with trastuzumab during pregnancy.
|
|
Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL
|
|
|
